VeriDose® DPYD Panel – Pioneering Customized Oncology Care
The VeriDose® DPYD Panel is a transformative genetic test crafted to detect individuals with DPD deficiencies, impacting the metabolism of select chemotherapy agents. This innovative approach empowers clinicians to tailor treatments, enhancing patient safety and outcomes.
By understanding these genetic nuances, the future of cancer therapy is more personalized than ever
Brochure
For any missing information or if you require additional details, please do not hesitate to contact us.
The VeriDose® DPYD Panel emerges as an avant-garde solution for accurate detection of dihydropyrimidine dehydrogenase (DPD) enzyme functionality variations. Its brilliance lies in its capability to concurrently detect a set of 9 DPYD variants associated with an increased risk of severe toxicity. Such a multiplexed detection system accelerates the diagnostic process, yielding decisive results efficiently.
A distinguishing feature of this panel is its integrated positive control system. Mimicking a heterozygous genotype, this control serves a dual purpose. It not only guarantees the impeccable functioning of the PCR system but also aids in streamlining the qualitative analysis interpretation.
Efficiency and Integration
Quality Assurance
Precision and Application
In summation, as pharmacogenetic analysis advances, tools like the VeriDose® DPYD Panel are at the forefront. This innovative product epitomizes not only scientific progression but also represents the future of precise and streamlined laboratory diagnostics.
For laboratory professionals navigating the choices of pharmacogenetic investigative tools, understanding the virtues of this panel is crucial. It presents a harmonious combination of efficiency, compliance, precision, and versatility—attributes highly valued in contemporary laboratories.
Amid the vast array of scientific equipment and tools, the VeriDose® DPYD Panel stands distinguished. It not only exemplifies the significant strides made in laboratory science but also the promising trajectory it is set upon.
Subscribe to our newsletter.